| |
| |
|
| Insider
Information: |
Smith Sandford D |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
386,982 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$925,106 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
386,982 |
|
|
| Total
Value |
$925,106 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
7
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -24.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ariad Pharmaceuticals Inc |
ARIA |
Director |
2007-06-20 |
131,205 |
2004-01-15 |
0 |
Premium* |
|
|
Genzyme Corp |
GENZ |
Exe VP,President Intl ... |
2011-04-04 |
0 |
2005-07-29 |
0 |
Premium* |
|
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
Director |
2016-11-29 |
0 |
2013-08-09 |
0 |
Premium* |
|
|
Palisade Bio Inc |
PALI |
Director |
2019-07-01 |
219,916 |
|
0 |
Premium* |
|
|
Seelos Therapeutics Inc |
SEEL |
Director |
2017-01-05 |
16,160 |
2014-10-22 |
0 |
Premium* |
|
|
Novelion Therapeutics Inc |
NVLN |
Director |
2017-01-27 |
900 |
2016-11-29 |
0 |
Premium* |
|
|
Cytokinetics Inc |
CYTK |
Director |
2024-01-02 |
18,801 |
2020-06-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
113 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.58 |
$2,813 |
D/D |
4,850 |
31,350 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
Director |
– • – |
2007-06-20 |
4 |
OE |
$1.50 |
$123,700 |
D/D |
45,000 |
131,205 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2014-10-22 |
4 |
B |
$1.52 |
$12,651 |
D/D |
8,300 |
8,300 |
2.39 |
- |
|
| AEGR |
Aegerion Pharmaceuticals,... |
Director |
– • – |
2016-07-27 |
4 |
D |
$1.55 |
$1,204 |
D/D |
(777) |
2,890 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2014-10-23 |
4 |
B |
$1.59 |
$28,998 |
D/D |
18,200 |
26,500 |
2.39 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
Director |
– • – |
2004-01-16 |
4 |
OE |
$2.00 |
$35,714 |
D/D |
17,857 |
56,205 |
|
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
Director |
– • – |
2004-11-29 |
4 |
OE |
$2.00 |
$20,000 |
D/D |
10,000 |
66,205 |
|
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
officerTitle |
– • – |
2005-12-01 |
4 |
OE |
$3.63 |
$36,300 |
D/D |
10,000 |
86,205 |
|
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-06-12 |
4 |
OE |
$4.02 |
$66,480 |
D/D |
15,045 |
4,166 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-06-22 |
4 |
OE |
$4.44 |
$44,400 |
D/D |
10,000 |
5,000 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-07-07 |
4 |
OE |
$6.21 |
$76,238 |
D/D |
11,742 |
6,510 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-07-08 |
4 |
OE |
$6.21 |
$8,905 |
D/D |
1,434 |
1,434 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-07-15 |
4 |
OE |
$6.21 |
$41,402 |
D/D |
6,667 |
6,667 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-06-15 |
4 |
OE |
$6.30 |
$41,996 |
D/D |
6,666 |
6,666 |
0 |
- |
|
| AEGR |
Aegerion Pharmaceuticals,... |
Director |
– • – |
2016-01-27 |
4 |
D |
$6.78 |
$5,275 |
D/D |
(778) |
1,445 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-06-17 |
4 |
OE |
$6.78 |
$46,994 |
D/D |
6,907 |
2,741 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-09 |
4 |
OE |
$6.82 |
$217,822 |
D/D |
27,582 |
5,295 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2020-10-05 |
4 |
OE |
$7.37 |
$43,748 |
D/D |
5,936 |
5,936 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-15 |
4 |
OE |
$8.75 |
$97,248 |
D/D |
10,714 |
6,634 |
0 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2017-01-27 |
4 |
D |
$9.38 |
$1,388 |
D/D |
(148) |
900 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-23 |
4 |
OE |
$9.45 |
$47,250 |
D/D |
5,000 |
5,920 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-26 |
4 |
OE |
$9.45 |
$47,250 |
D/D |
5,000 |
5,920 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-11-19 |
4 |
OE |
$9.45 |
$382,247 |
D/D |
29,032 |
10,797 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-04-27 |
4 |
OE |
$10.55 |
$103,396 |
D/D |
9,739 |
5,920 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
– • – |
2021-07-19 |
4 |
OE |
$10.68 |
$127,786 |
D/D |
11,965 |
11,459 |
0 |
- |
|
113 Records found
|
|
Page 2 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
